Technical Analysis for GDTC - CytoMed Therapeutics Limited
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Crossed Above 20 DMA | Bullish | -4.36% | |
Calm After Storm | Range Contraction | -4.36% | |
Wide Bands | Range Expansion | -4.36% | |
Gapped Up | Strength | -4.36% | |
Fell Below 20 DMA | Bearish | 3.57% | |
MACD Bearish Signal Line Cross | Bearish | 3.57% | |
Boomer Buy Setup | Bullish Swing Setup | 3.57% | |
Calm After Storm | Range Contraction | 3.57% |
Alert | Time |
---|---|
Fell Below 20 DMA | about 22 hours ago |
20 DMA Support | 1 day ago |
Down 5% | 1 day ago |
Down 3% | 1 day ago |
Down 2 % | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 05/29/2024
CytoMed Therapeutics Limited Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immune System Immunotherapy Cancer Treatment Immunotherapies Virotherapy Chimeric Antigen Receptor T Cell Natural Killer Cell Lymphocytes T Cells Human Cancers Pre Clinical Biopharmaceutical
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 5.5 |
52 Week Low | 1.2 |
Average Volume | 12,452 |
200-Day Moving Average | 2.12 |
50-Day Moving Average | 1.86 |
20-Day Moving Average | 2.31 |
10-Day Moving Average | 2.53 |
Average True Range | 0.28 |
RSI (14) | 53.05 |
ADX | 38.09 |
+DI | 31.84 |
-DI | 14.69 |
Chandelier Exit (Long, 3 ATRs) | 2.72 |
Chandelier Exit (Short, 3 ATRs) | 2.53 |
Upper Bollinger Bands | 2.90 |
Lower Bollinger Band | 1.72 |
Percent B (%b) | 0.5 |
BandWidth | 51.29 |
MACD Line | 0.17 |
MACD Signal Line | 0.21 |
MACD Histogram | -0.0325 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.56 | ||||
Resistance 3 (R3) | 2.58 | 2.52 | 2.52 | ||
Resistance 2 (R2) | 2.52 | 2.45 | 2.51 | 2.51 | |
Resistance 1 (R1) | 2.41 | 2.41 | 2.38 | 2.39 | 2.49 |
Pivot Point | 2.34 | 2.34 | 2.33 | 2.33 | 2.34 |
Support 1 (S1) | 2.24 | 2.28 | 2.20 | 2.22 | 2.12 |
Support 2 (S2) | 2.17 | 2.24 | 2.16 | 2.10 | |
Support 3 (S3) | 2.06 | 2.17 | 2.09 | ||
Support 4 (S4) | 2.05 |